Do Verve's gene edits pass down to patients' children? The FDA wants to know
By Nick Paul Taylor,
Fierce Biotech
| 12. 05. 2022
The FDA has set out its reasons for putting Verve Therapeutics’ high cholesterol gene editing therapy on hold. Officials want additional data to allay concerns that patients could pass on the edited genes to their children before they lift the clinical hold.
Last month, the FDA put Verve’s application on hold and vowed to send an official letter setting out its questions within 30 days. Verve now has the letter—and knows what needs to be done to get the clinical trial of its PCSK9-deactivating drug candidate VERVE-101 off the ground.
The FDA has asked for more preclinical data on potency differences between human and non-human cells, the risks of germline editing and off-target analyses in non-hepatocyte cell types. Officials also want Verve to share data from the heart-1 trial, which continues to enroll patients in New Zealand and the U.K., and to tweak the protocol to mitigate the risks of the therapy.
Specifically, the FDA has asked Verve to incorporate additional contraceptive measures and to increase the length of the staggering interval between dosing of participants. Verve plans to submit...
Related Articles
By Carl Zimmer, The New York Times | 06.04.2026
Scientists at Columbia University have edited the DNA of early human embryos with unprecedented accuracy, an achievement that could open the way to babies engineered with particular characteristics.
The prospect has fueled controversy for years. On the one hand, the...
Faster, Higher, Stronger was the Olympic motto from 1874 until 2001, when “ – Together” was added, to stress the “moral and educational perspective” of the Games. The folks who paid for or participated in the Enhanced Games – the name itself a nod to the Olympics – held in Las Vegas on Sunday, May 24, apparently use a different edit:
Faster, Higher, Stronger with Chemistry
High-level sport draws huge crowds. Coming very soon, the soccer World Cup, featuring...
By Gina Kolata, The New York Times | 05.25.2026
In a small, preliminary study, an experimental gene-editing treatment dramatically lowered cholesterol levels, perhaps permanently, after just one infusion, scientists reported on Monday.
If confirmed in larger studies, researchers hope the findings may lead to a one-and-done way to prevent...
By Ryan Cross, Endpoint News | 05.20.2026
BOSTON — Over the past year, I’ve begun hearing rumblings from scientists who secretly think it’s time to stop being stodgy about editing the genes of human embryos.
For the most part, they are still too timid to speak up...
